Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Inari Medical, Inc. (NASDAQ: NARI ) reported an adjusted loss per share of 41 cents in the second quarter of 2024 compared with the year-ago period''s loss of 4 cents per share. The Zacks Consensus Estimate for loss per share was pegged at 16 cents. On a GAAP basis, the company recorded a loss per share of 54 cents. There was no adjustment in the prior-year period. Revenues in Detail Inari Medical registered revenues of $145.8 million in the second quarter, up 22.5% year over year. The figure beat the Zacks Consensus Estimate by 1.3%. Q2 Highlights According to management, Inari Medical saw record cases and revenue generation outside of the United States in the second quarter. Increased adoption of Inari Medical''s products in Western Europe was the main factor driving its performance and excellent case growth in early-stage markets in Latin America, Canada, and the Asia-Pacific region. The company is expecting to start treating patients in China and Japan in 2024, and it is currently making good progress in both regions.
https://www.investing.com/news/company-news/inari-medical-shares-target-cut-hold-rating-reiterated-by-truist-securities-93CH-3546414
https://www.investing.com/news/company-news/inari-medical-shares-target-cut-maintains-rating-on-q2-performance-93CH-3546413
Inari Medical (NASDAQ: NARI ) just reported results for the second quarter of 2024. Inari Medical reported earnings per share of -48 cents. This was below the analyst estimate for EPS of -13 cents. The company reported revenue of $145.82 million. This was 1.45% better than the analyst estimate for revenue of $143.73 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post NARI Stock Earnings: Inari Medical Misses EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
Start Time: 16:30 January 1, 0000 2:24 PM ETInari Medical, Inc.
Inari Medical (NARI) has provided an announcement. Inari Medical, Inc. announces the retirement of CFO Mitch Hill, effective October 1, 2024, after…
No summary available.
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024.
